Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Boston Technology Review.
Press releases published on May 20, 2025
Enlivex Selected to Present at Israeli BioMed 2025 Conference
GlobeNewswire
·
May 20, 2025
Presentation to highlight Allocetra™ and the therapeutic potential of macrophage reprogramming in inflammatory diseases Ness-Ziona, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage …
Magnite and Amazon Publisher Services (APS) Collaborate to Enable New Streaming TV Opportunities via APS Transparent Ad Marketplace (TAM)
GlobeNewswire
·
May 20, 2025
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- Amazon Publisher Services (APS) and Magnite (NASDAQ: MGNI), the largest independent sell-side advertising company, have announced a deeper streaming TV collaboration through APS' Transparent Ad Marketplace (TAM) …
Employ Appoints Suzanne Tran as Chief Marketing Officer to Drive Growth and Market Impact
GlobeNewswire
·
May 20, 2025
DENVER, May 20, 2025 (GLOBE NEWSWIRE) -- Employ Inc., the market-leading intelligent hiring suite powered by AI, announced today the appointment of Suzanne Tran as Chief Marketing Officer. Tran will be responsible for building and scaling Employ’s go-to- …
Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast
GlobeNewswire
·
May 20, 2025
GARDEN CITY, N.Y., May 20, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives …
SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase
GlobeNewswire
·
May 20, 2025
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, …
PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase
GlobeNewswire
·
May 20, 2025
PRINCETON, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced …
Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025
GlobeNewswire
·
May 20, 2025
- Key Opinion Leaders (KOLs) on Absence seizures include Dennis Dlugos, MD, Wendyl D’Souza, MBChB, MPH, FRACP, PhD, and Alexander Rotenberg, MD, PhD - VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) ( …
aTyr Pharma to Present at Upcoming Investor Conferences
GlobeNewswire
·
May 20, 2025
SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that …
Marine Biologics Expands Leadership Team to Drive Next Phase of Growth
GlobeNewswire
·
May 20, 2025
BERKELEY, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Biomaterials company Marine Biologics today introduced Danièle Karleskind, Ph.D. as its new Chief Operations Officer and Ryan Hunt as Director of Business Development. With more than 55 years of combined …
ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event
GlobeNewswire
·
May 20, 2025
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity - Following recent …
Praxis Precision Medicines to Participate in Upcoming Conferences
GlobeNewswire
·
May 20, 2025
BOSTON, May 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …
Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD
GlobeNewswire
·
May 20, 2025
Subjects Demonstrated Marked Improvement of ADHD Symptoms at Week 5 New Drug Application on Schedule for this Summer CING CEO Shares Insights and Strategic Outlook on “Unboxing Biotech” Podcast KANSAS CITY, Kan., May 20, 2025 (GLOBE NEWSWIRE) -- Cingulate …
Duos Technologies Appoints Retired Brigadier General Craig Nixon as Chairman of the Board of Directors
GlobeNewswire
·
May 20, 2025
JACKSONVILLE, Fla., May 20, 2025 (GLOBE NEWSWIRE) -- Duos Technologies Group, Inc. (“Duos” or the “Company”) (Nasdaq: DUOT), today announced the appointment of Brigadier General (Ret.) James Craig Nixon as the new Chairman of its Board of Directors, …
Spectral AI Research Partner Using DeepView System Wins Best Research Project at the 2025 Education Awards
GlobeNewswire
·
May 20, 2025
DALLAS, May 20, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ: MDAI) (“Spectral AI” or the “Company”), a leading developer of the AI-driven DeepView® System, which uses multi-spectral imaging and AI algorithms to predict burn healing potential today …
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection
GlobeNewswire
·
May 20, 2025
RADNOR, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and …
Philikos announces initiation of clinical Phase 1/2 study with T-Guard® in patients with systemic sclerosis
GlobeNewswire
·
May 20, 2025
NIJMEGEN, the Netherlands, May 20, 2025 (GLOBE NEWSWIRE) -- Philikos B.V., a Dutch biotechnology company developing antibody-based therapies to treat severe immune disorders, today announced that it has enrolled the first patient in a Phase 1/2 clinical …
Philikos kondigt de start aan van een klinische fase 1/2-studie met T-Guard® bij patiënten met systemische sclerose
GlobeNewswire
·
May 20, 2025
NIJMEGEN, the Netherlands, May 20, 2025 (GLOBE NEWSWIRE) -- Philikos B.V., een Nederlands biotechnologiebedrijf dat op antilichamen gebaseerde therapieën ontwikkelt voor de behandeling van ernstige immuunziekten, heeft vandaag aangekondigd dat de eerste …
Dogecoin XRP and Solana Price Prediction: Why Holders Are Flocking to XY Miners for Passive Income?
GlobeNewswire
·
May 20, 2025
Los Angeles, California, May 20, 2025 (GLOBE NEWSWIRE) -- Cryptocurrency markets reacted to the SEC's delayed ETF decision, with XRP, Solana (SOL), and Dogecoin (DOGE) all seeing price volatility. Traders are keeping a close eye on these assets to gauge …
MicroAlgo Inc. Researches Quantum Machine Learning Algorithms to Accelerate Machine Learning Tasks
GlobeNewswire
·
May 20, 2025
shenzhen, May 20, 2025 (GLOBE NEWSWIRE) -- Shenzhen, May. 20, 2025/––MicroAlgo Inc. (the "Company" or "MicroAlgo") (NASDAQ: MLGO), announced that quantum algorithms will be deeply integrated with machine learning to explore practical application scenarios …
Biometric Identity and Access Management Software Solutions Provider BIO-key Announces Two Webcast Investor Presentations: Aegis Capital Thu. May 22 at 11:30am ET and Maxim Group Wed. June 4 at 11am ET
GlobeNewswire
·
May 20, 2025
HOLMDEL, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and tokenless, Identity-Bound …